Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of Investors

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Voyager Therapeutics for possible violations of federal securities laws and unlawful business practices [1][3]. Company Developments - On February 11, 2025, Voyager announced it would assess alternate payloads for its gene therapy program targeting SOD1 amyotrophic lateral sclerosis (ALS), citing emerging preclinical data indicating that the siRNA payload component of VY9323 does not meet their standards due to off-target effects [3]. - Voyager stated it no longer anticipates filing an investigational new drug (IND) application for VY9323 in mid-2025 [3]. - Following this announcement, Voyager's share price fell by $1.11, or approximately 20$5.32 on February 10, 2025, to $4.41 on February 11, 2025 [3].